Cited by 144Monoclonal and Polyclonal Antibodies ResearchBiosimilars and Bioanalytical MethodsPharmaceutical studies and practices

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look

Ling, Jie, Zhou, Honghui, Jiao, Qun, Davis, Hugh M.·2009·The Journal of Clinical Pharmacology

DOI 10.1177/0091270009337134

Open this paper in CoChat — free account

Abstract

The authors evaluated interspecies scaling for the prediction of human clearance of 18 therapeutic monoclonal antibodies (mAbs). Human and monkey/chimpanzee data of 14 mAbs were classified based on the targeted antigens (soluble or membrane bound). Simple allometry and/or a time‐invariant method (elementary Dedrick plot) were performed. Results indicate that human clearance might be accurately predicted from monkey data for mAbs targeting soluble receptors or membrane‐bound receptors with limited tissue distribution using simplified allometry. The optimal exponents were estimated to be 0.85 or 0.90. If nonlinearity is anticipated at the human efficacious dose, pharmacokinetic parameters obtained at high doses in animals might not be sufficient for full pharmacokinetic characterization and prediction. Using prespecified criteria, including predicted human clearance (≤ or > 10 mL/d/kg), simplified allometric scaling might be helpful in predicting the effect of receptor‐mediated clearance for mAbs targeting membrane‐bound antigens. Furthermore, simplified allometry and an elementary Dedrick plot provide similar results in predicted clearance. Given the significant advantages offered by simplified allometry, it should be used when data are available from only 1 species. When reasonable data from ≥3 species are available, traditional allometry should be explored. Overall, clearance prediction is useful for human dose prediction in drug discovery and development.

Integrity signals

Registry

Crossref · 10.1177/0091270009337134

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,930
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N. M., Guzzo, C. A., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,870
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Papp, K. A., Langley, R. G. B., Lebwohl, M., Krueger, G. G., Szapary, P. O., Yeilding, N. M., Guzzo, C. A., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,358
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer
Gordon, M. S., Margolin, K. A., Talpaz, M., Sledge, G. W., Holmgren, E. B., Benjamin, R. S., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
Antibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Sun, K. (2005) · Chinese New Drugs Journal · Cited by 762
Monoclonal antibody successes in the clinic
Reichert, J. M., Rosensweig, C., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 741
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall’Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 648

Show all 68 references

Research works printed but not linked: 22

Food and Drug Administration (FDA)., 2002, Guidance for Industry: Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers
Teorell T., 1937, Kinetics of distribution of substances administered to the body, Arch Intern Pharmacodyn, 57, 205
Mahmood I., 2004, Pharmacokinetics in Drug Development: Clinical Study Design and Analysis, 423
Tysabri (natalizumab) pharmacology review.www.fda.govcderfoinda2004125104s000Natalizumab.htm.
Raptiva (efalizumab) pharmacology review.http:www.fda.govcderfoinda20031250750000RaptivaPharmrP1.pdf.
2005, Zenapax [package insert]
2008, Raptiva [package insert]
2008, Remicade [package insert]
2008, Erbitux [package insert]
2008, Avastin [package insert]
2008, Herceptin [package insert]
2008, Vectabix [package insert]
2008, Tysabri [package insert]
Erbitux (cetuximab) pharmacology review.http:www.fda.govcderbiologicsnda125084ERBITUXBIOPHARMR.PDF.
Zenapax (daclizumab) nonclinical pharmacology and toxicology review.http:www.fda.govcderbiologicsreviewdaclhof121097r2.pdf.
Gabrielsson J, 2000, Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts & Applications
DengR MortensenD PrabhuS et al.Prediction of human pharmacokinetics for monoclonal antibody. Presented at: AAPS National Biotechnology Conference;June 2427 2007; San Diego CA.
2008, Rituxan [package insert]
Vozeh S, 1989, Pharmacokinetic Drug Data: Clinical Pharmacokinetic Drug Data Handbook
Mahmood I., 2005, Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling
2009, Simponi [package insert]
Herceptin (trastuzumab) clinical pharmacology review.http:www.fda.govcderbiologicsreviewtrasgen092598r3.pdf.

Sorted by citations

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liming, L. (2017) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 407
Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned?
Deng, R., Iyer, S., Theil, F.-P., Mortensen, D. L., Fielder, P. J., & Prabhu, S. (2011) · mAbs · doi:10.4161/mabs.3.1.13799 · Cited by 285
Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
Dostálek, M., Gardner, I. B., Gurbaxani, B. M., Rose, R. H., & Chetty, M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0027-4 · Cited by 236
Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences
Wang, W., Lü, P., Fang, Y., Hamuro, L., Pittman, T. J., Carr, B. I., Hochman, J. H., & Prueksaritanont, T. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039453 · Cited by 171
Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies
Kamath, A. V. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.09.004 · Cited by 164
Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies: Retrospective Analysis of Monkey as a Single Species for First-in-Human Prediction
Dong, J. Q., Salinger, D. H., Endres, C. J., Gibbs, J. P., Hsu, C.-P., Stouch, B. J., Hurh, E., & Gibbs, M. A. (2011) · Clinical Pharmacokinetics · doi:10.2165/11537430-000000000-00000 · Cited by 156
Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration
Zheng, Y., Tesar, D. B., Benincosa, L., Birnböck, H., Boswell, C. A., Bumbaca, D., Cowan, K. J., Danilenko, D. M., Daugherty, A. L., Fielder, P. J., et al. (2012) · mAbs · doi:10.4161/mabs.4.2.19387 · Cited by 149
Pharmacokinetic Considerations for Antibody Drug Conjugates
Lin, K., & Tibbitts, J. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0800-y · Cited by 136
Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
Deng, R., Jin, F., Prabhu, S., & Iyer, S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.643868 · Cited by 126
Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody
Singh, S., Kroe‐Barrett, R., Canada, K. A., Zhu, X., Sepulveda, E., Wu, H. H., Ya-qin, H., Raymond, E. L., Ahlberg, J., Frego, L., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1032491 · Cited by 124
Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach
Betts, A. M., Keunecke, A., van Steeg, T. J., van der Graaf, P. H., Avery, L. B., Jones, H. M., & Berkhout, J. (2018) · mAbs · doi:10.1080/19420862.2018.1462429 · Cited by 114
Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies
Avery, L. B., Wang, M., Kavosi, M. S., Joyce, A. P., Kurz, J. C., Fan, Y., Dowty, M. E., Zhang, M., Zhang, Y., Cheng, A., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1193660 · Cited by 109
Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited
Wang, W., & Prueksaritanont, T. (2010) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.708 · Cited by 104
Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics
Avery, L. B., Wade, J. M., Wang, M., Tam, A. S. P., King, A. C., Piche‐Nicholas, N., Kavosi, M. S., Penn, S., Cirelli, D. J., Kurz, J. C., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1417718 · Cited by 99
Interspecies Scaling and Prediction of Human Clearance: Comparison of Small- and Macro-Molecule Drugs
Huh, Y., Smith, D. E., & Rose Feng, M. (2011) · Xenobiotica · doi:10.3109/00498254.2011.598582 · Cited by 98
Pharmacokinetic Modeling of the Subcutaneous Absorption of Therapeutic Proteins
Kagan, L. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059121 · Cited by 92
In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies
Bown, H. K., Bonn, C., Yohe, S. T., Yadav, D. B., Patapoff, T. W., Daugherty, A. L., & Mrsny, R. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.015 · Cited by 92
Half-life extension using serum albumin-binding DARPin® domains
Steiner, D., Merz, F., Sonderegger, I., Gulotti-Georgieva, M., Villemagne, D., Phillips, D. J., Forrer, P., Stumpp, M. T., Zitt, C., & Binz, H. K. (2017) · Protein Engineering Design and Selection · doi:10.1093/protein/gzx022 · Cited by 89
Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non‐Hodgkin's Lymphoma and Exposure–Response in CLL
Gibiansky, E., Gibiansky, L. V., Carlile, D. J., Jamois, C., Buchheit, V., & Frey, N. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.42 · Cited by 88
Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies
Glassman, P. M., & Balthasar, J. P. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9482-0 · Cited by 88
A Model-Based Approach to Predicting the Human Pharmacokinetics of a Monoclonal Antibody Exhibiting Target-Mediated Drug Disposition
Luu, K. T., Bergqvist, S., Chen, E., Hu‐Lowe, D. D., & Kraynov, E. A. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.191999 · Cited by 82
Prediction of Human Pharmacokinetics of Therapeutic Monoclonal Antibodies from Simple Allometry of Monkey Data
Oitate, M., Masubuchi, N., Ito, T., Yabe, Y., Karibe, T., Aoki, T., Murayama, N., Kurihara, A., Okudaira, N., & Izumi, T. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rg-011 · Cited by 81
On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach
Haddish‐Berhane, N., Shah, D. K., Ma, D., Leal, M., Gerber, H., Sapra, P., Barton, H. A., & Betts, A. M. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9329-x · Cited by 79
Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model
Zhao, J., Cao, Y., & Jusko, W. J. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1703-5 · Cited by 78
Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development
Wang, J., Iyer, S., Fielder, P. J., Davis, J. D., & Deng, R. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1952 · Cited by 69
An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies
Ko, S., Park, S., Sohn, M. H., Jo, M., Ko, B. J., Na, J., Yoo, H., Jeong, A. L., Ha, K., Woo, J. R., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00870-5 · Cited by 71
Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities
Tam, S. H., McCarthy, S. G., Brosnan, K., Goldberg, K. M., & Scallon, B. J. (2013) · mAbs · doi:10.4161/mabs.23836 · Cited by 71
Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate
Binz, H. K., Bakker, T. R., Phillips, D. J., Cornelius, A., Zitt, C., Göttler, T., Sigrist, G., Fiedler, U., Ekawardhani, S., Dolado, I., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1305529 · Cited by 65
Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A
Gupta, P., Kamath, A. V., Park, S., Chiu, H. H., Lutman, J., Maia, M., Tan, M., Xu, M., Swem, L. R., & Deng, R. (2016) · mAbs · doi:10.1080/19420862.2016.1167294 · Cited by 57
Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer
Xiang, H., Chan, A., Ahene, A., Bellovin, D., Deng, R., Hsu, A. W., Jeffry, U., Palencia, S., Powers, J. M., Zanghi, J., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1981202 · Cited by 56
Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings
Germovsek, E., Cheng, M., & Giragossian, C. (2021) · mAbs · doi:10.1080/19420862.2021.1964935 · Cited by 56
Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition
Singh, A. P., Krzyżański, W., Martin, S. W., Weber, G. L., Betts, A. M., Ahmad, A. M., Abraham, A. K., Zutshi, A., Lin, J., & Singh, P. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9690-8 · Cited by 53
A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design
Davda, J. P., Dodds, M., Gibbs, M. A., Wisdom, W., & Gibbs, J. P. (2014) · mAbs · doi:10.4161/mabs.29095 · Cited by 53
Mechanistic Projection of First‐in‐Human Dose for Bispecific Immunomodulatory P‐Cadherin LP‐DART: An Integrated PK/PD Modeling Approach
Chen, X., Haddish‐Berhane, N., Moore, P. A., Clark, T., Yang, Y., Li, H., Xuan, D., Barton, H. A., Am, B., & Barletta, F. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.393 · Cited by 52
Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies
Johnson, D. E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113685 · Cited by 48
A Physiologically‐Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data
Jones, H. M., Zhang, Z., Jasper, P., Luo, H., Avery, L. B., King, L. E., Neubert, H., Barton, H. A., Betts, A. M., & Webster, R. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12461 · Cited by 48
Whole-Body Pharmacokinetics of Antibody in Mice Determined using Enzyme-Linked Immunosorbent Assay and Derivation of Tissue Interstitial Concentrations
Chang, H., Kim, S. J., & Shah, D. K. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.05.025 · Cited by 48
Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates
Dostalek, M., Prueksaritanont, T., & Kelley, R. F. (2017) · mAbs · doi:10.1080/19420862.2017.1323160 · Cited by 45
Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human
Haraya, K., Tachibana, T., & Nezu, J. (2017) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2017.05.002 · Cited by 43
Prediction of Exposure–Response Relationships to Support First-in-Human Study Design
Gibbs, J. P. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9236-7 · Cited by 43
Preclinical and translational pharmacokinetics of a novel THIOMAB™ antibody-antibiotic conjugate againstStaphylococcus aureus
Deng, R., Zhou, C., Li, D., Cai, H., Sukumaran, S., Carrasco‐Triguero, M., Saad, O. M., Nazzal, D., Lowe, C., Ramanujan, S., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1627152 · Cited by 42
Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to Humans
Xin, Y., Bai, S., Damico‐Beyer, L. A., Jin, D., Liang, W., Wu, Y., Theil, F., Joshi, A., Lu, Y., Lowe, J. A., III, et al. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0781-x · Cited by 38
Prediction of Human Plasma Concentration-time Profiles of Monoclonal Antibodies from Monkey Data by a Species-invariant Time Method
Oitate, M., Nakayama, S., Ito, T., Kurihara, A., Okudaira, N., & Izumi, T. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-sh-059 · Cited by 35
Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation
Haraya, K., Tsutsui, H., Komori, Y., & Tachibana, T. (2022) · Pharmaceuticals · doi:10.3390/ph15050508 · Cited by 35
Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data
Li, C., Zhang, C., Deng, R., Leipold, D. D., Li, D., Latifi, B., Gao, Y., Zhang, C., Li, Z., Miles, D., et al. (2019) · Clinical and Translational Science · doi:10.1111/cts.12649 · Cited by 34
Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
Lucas, A. T., Robinson, R., Schorzman, A. N., Piscitelli, J. A., Razo, J. F., & Zamboni, W. C. (2019) · Antibodies · doi:10.3390/antib8010003 · Cited by 31
Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody
Haraya, K., Tachibana, T., Nanami, M., & Ishigai, M. (2014) · Xenobiotica · doi:10.3109/00498254.2014.941963 · Cited by 30
Considerations on the Calculation of the Human Equivalent Dose from Toxicology Studies for Biologic Anticancer Agents
Elmeliegy, M. A., Udata, C., Liao, K., & Yin, D. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-00987-2 · Cited by 30
A semi‐mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first‐in‐human single ascending dose study
Salinger, D. H., Endres, C. J., Martin, D. A., & Gibbs, M. A. (2014) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.103 · Cited by 29
Choosing the Allometric Exponent in Covariate Model Building
Sinha, J., Al-Sallami, H. S., & Duffull, S. B. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0667-0 · Cited by 27
Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody
Xue, J., Kong, D., Yao, Y., Yang, L., Yao, Q., Zhu, Y., Ding, Y., Yang, F., Gong, J., Shen, L., et al. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.06.015 · Cited by 25
A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide
Offman, E. M., & Edginton, A. N. (2015) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-015-9406-4 · Cited by 26
Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper
Ménochet, K., Yu, H., Wang, B., Tibbitts, J., Hsu, C., Kamath, A. V., Richter, W. F., & Baumann, A. (2022) · mAbs · doi:10.1080/19420862.2022.2145997 · Cited by 25
Bioanalysis of Target Biomarker And Pk/Pd Relevancy During The Development of Biotherapeutics
Lee, J. W., & Salimi-Moosavi, H. (2012) · Bioanalysis · doi:10.4155/bio.12.220 · Cited by 24
Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma
Kamath, A. V., Lu, D., Gupta, P., Jin, D., Xin, Y., Brady, A., Stéphan, J.-P., Li, H., Tien, J., Qing, J., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1807-5 · Cited by 22
Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
Gibiansky, E., Gibiansky, L. V., Chavanne, C., Frey, N., & Jamois, C. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12665 · Cited by 21
Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B
Vugmeyster, Y., Rohde, C. M., Perreault, M., Gimeno, R. E., & Singh, P. (2013) · mAbs · doi:10.4161/mabs.23826 · Cited by 22
Model‐Based Assessment of Dosing Strategies in Children for Monoclonal Antibodies Exhibiting Target‐Mediated Drug Disposition
Zheng, S., Gaitonde, P., Andrew, M., Gibbs, M. A., Lesko, L. J., & Schmidt, S. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.38 · Cited by 21
Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection
Pasquiers, B., Benamara, S., Felices, M., Nguyen, L., & Declèves, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112754 · Cited by 20
Approaches for predicting human pharmacokinetics using interspecies pharmacokinetic scaling
Kang, H. E., & Lee, M. G. (2011) · Archives of Pharmacal Research · doi:10.1007/s12272-011-1101-4 · Cited by 21
Mechanistic Investigation of the Preclinical Pharmacokinetics and Interspecies Scaling of PF-05231023, a Fibroblast Growth Factor 21–Antibody Protein Conjugate
Giragossian, C., Vage, C., Li, J., Pelletier, K. B., Piche‐Nicholas, N., Rajadhyaksha, M., Liras, J. L., Logan, A., Calle, R. A., & Weng, Y. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061713 · Cited by 20
Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method
Song, L., Xue, J., Zhang, J., Li, S., Liu, D., & Zhou, T. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105584 · Cited by 19
Population physiologically-based pharmacokinetic model incorporating lymphatic uptake for a subcutaneously administered pegylated peptide
Offman, E. M., Phipps, C. J., & Edginton, A. N. (2016) · In Silico Pharmacology · doi:10.1186/s40203-016-0018-5 · Cited by 19
Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies
Hu, L., & Hansen, R. J. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23504 · Cited by 16
Predicting human pharmacokinetics from preclinical data: clearance
Yim, D., Bae, S., & Choi, S. (2021) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2021.29.e12 · Cited by 15
Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development
Liao, M. Z., Leipold, D. D., Chen, S., Li, Z., Kamath, A. V., & Li, C. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2351044 · Cited by 15
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
Shastri, P. N., Shah, N., Lechmann, M., Mody, H. R., Retter, M. W., Zhu, M., Li, T. R., Wang, J., Shaik, M. N., Zheng, X., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3439 · Cited by 15
Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates
Bouillon‐Pichault, M., Brillac, C., Amara, C., Nicolazzi, C., Fagniez, N., Fau, J., Koiwai, K., Ziti‐Ljajic, S., & Veyrat‐Follet, C. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.869 · Cited by 15
Non‐Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First‐in‐Human Dose Selection for CNTO 5825, an Anti‐Interleukin‐13 Monoclonal Antibody
Nnane, I. P., Xu, Z., Zhou, H., & Davis, H. M. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12391 · Cited by 14
Self-citation
ADME of Monoclonal Antibody Biotherapeutics: Knowledge Gaps and Emerging Tools
Lee, J. W. (2013) · Bioanalysis · doi:10.4155/bio.13.144 · Cited by 14
Monoclonal Antibodies: From Structure to Therapeutic Application
Davis, J. D., Deng, R., Boswell, C. A., Zhang, Y., Li, J., Fielder, P. J., Joshi, A., & Kenkare-Mitra, S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6486-0_7 · Cited by 14
Pharmacokinetics and Toxicokinetics
Schrag, M. L., & Regal, K. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-803620-4.00004-9 · Cited by 14
Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies
Zhu, M., Olson, K., Kirshner, J. R., Toroghi, M. K., YAN, H. H., Haber, L., Meagher, C. T., Flink, D. M., Ambati, S. R., Davis, J. D., et al. (2022) · Clinical and Translational Science · doi:10.1111/cts.13212 · Cited by 12
Translational kinetic‐pharmacodynamics of mRNA‐6231, an investigational mRNA therapeutic encoding mutein interleukin‐2
Rajlic, I. L., Guglieri-López, B., Rangoonwala, N., Ivaturi, V. D., Van, L. M., Mori, S., Wipke, B. T., Burdette, D. S., & Attarwala, H. Z. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13142 · Cited by 13
Translational pharmacokinetic/pharmacodynamic model for mRNA‐0184, an investigational therapeutic for the treatment of heart failure
Kaushal, N., Attarwala, H. Z., Iqbal, M. J., Saini, R., Van, L. M., & Liang, M. (2024) · Clinical and Translational Science · doi:10.1111/cts.13894 · Cited by 14
Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research
Zhang, Y., Doshi, S., & Zhu, M. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12663 · Cited by 13
Use of a Target‐Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC 1118, an Anti‐epidermal Growth Factor Receptor Antibody
Park, W., Han, S., Lee, J.-T., Hong, T., Won, J., Lim, Y., Lee, K., Byun, H. Y., & Yim, D. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12675 · Cited by 13
A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans
Biliouris, K., Nestorov, I. A., Naik, H., Dai, D., Xiao, G., Wang, Q. L., Pellerin, A., Rabah, D., Lesko, L. J., & Trame, M. N. (2018) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-018-9609-6 · Cited by 13
Pharmacokinetic Properties of Humanized IgG1 and IgG4 Antibodies in Preclinical Species: Translational Evaluation
Tabrizi, M. A., Neupane, D., Elie, S. E., Shankaran, H., Juan, V., Zhang, S., Hseih, S., Fayadat‐Dilman, L., Zhang, D., Song, Y., et al. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0304-3 · Cited by 13
Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration–effect relationship support clinical dose and regimen selection
Xiang, H., Reyes, A. E., Eppler, S., Kelley, S. K., & Damico‐Beyer, L. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2200-3 · Cited by 12
Monoclonal Antibodies: Interspecies Scaling With Minimal Preclinical Information
Han, C., & Zhou, H. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.1 · Cited by 12
Self-citation
Pharmacometric modeling of lipid nanoparticle-encapsulated mRNA therapeutics and vaccines: A systematic review
Zhang, M., Van, L. M., & Amiji, M. M. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102686 · Cited by 11
A Single Animal Species-Based Prediction of Human Clearance and First-in-Human Dose of Monoclonal Antibodies: Beyond Monkey
Mahmood, I. (2021) · Antibodies · doi:10.3390/antib10030035 · Cited by 11
Characterization and Interspecies Scaling of rhTNF-α Pharmacokinetics with Minimal Physiologically Based Pharmacokinetic Models
Chen, X., DuBois, D. C., Almon, R. R., & Jusko, W. J. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074799 · Cited by 10
Interspecies Scaling of Antibody–Drug Conjugates (ADC) for the Prediction of Human Clearance
Mahmood, I. (2021) · Antibodies · doi:10.3390/antib10010001 · Cited by 9
Predicting Method for the Human Plasma Concentration–Time Profile of a Monoclonal Antibody from the Half-life of Non-human Primates
Nakamura, G., Ozeki, K., Nagayasu, M., Nambu, T., Nemoto, T., & Hosoya, K. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-01042 · Cited by 10
Rat as a Predictive Model for Human Clearance and Bioavailability of Monoclonal Antibodies
Robarge, J., Budge, K. M., Her, L., Patterson, A. M., & Brown‐Augsburger, P. (2024) · Antibodies · doi:10.3390/antib14010002 · Cited by 8
Comparison of Various Approaches to Translate Non-Linear Pharmacokinetics of Monoclonal Antibodies from Cynomolgus Monkey to Human
Singh, R., Moreno, M., & Stanimirovic, D. B. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00691-3 · Cited by 8
Translation of the efficacy of antibody–drug conjugates from preclinical to clinical using a semimechanistic PK / PD model: A case study with RC88
Li, Q., Wang, L., Zhang, J., Zhao, G., Liu, Z., Ma, X., & Jiang, J. (2023) · Clinical and Translational Science · doi:10.1111/cts.13526 · Cited by 7
Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5)
Ahlberg, J., Giragossian, C., Li, H., Myzithras, M., Raymond, E., Caviness, G. O., Grimaldi, C. M., Brown, S.-E., Perez, R., Yang, D., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1615345 · Cited by 8
A Single-Species Approach Considering Additional Physiological Information for Prediction of Hepatic Clearance of Glycoprotein Derivate Therapeutics
Poulin, P. (2011) · Clinical Pharmacokinetics · doi:10.2165/11592610-000000000-00000 · Cited by 8
Pharmacokinetics and Toxicokinetics
Schrag, M. L., & Regal, K. A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387815-1.00003-4 · Cited by 7
Utilizing PK and PD Biomarkers to Guide the First-in-Human Starting Dose Selection of MTBT1466A: A Novel Humanized Monoclonal Anti-TGFβ3 Antibody for the Treatment of Fibrotic Diseases
Yadav, R., Sukumaran, S., Lutman, J., Mitra, M. S., Halpern, W., Sun, T., Setiadi, A., Neighbors, M., Sheng, X. R., Yip, V., et al. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.07.005 · Cited by 6
Contrasting toxicokinetic evaluations and interspecies pharmacokinetic scaling approaches for small molecules and biologics: applicability to biosimilar development
Offman, E. M., & Edginton, A. N. (2012) · Xenobiotica · doi:10.3109/00498254.2012.744113 · Cited by 6
Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncology
Saber, H., Thompson, M. D., & Leighton, J. K. (2024) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2024.105616 · Cited by 5
Pharmacokinetics and Pharmacodynamics of CD4-Anchoring Bi-Functional Fusion Inhibitor in Monkeys
Liu, X., Ou, Y. C., Zhang, J., Ahene, A. B., Clark, D., Hsieh, S., Cooper, M., & Ji, C. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1203-4 · Cited by 5
Model-Based Interspecies Scaling for Predicting Human Pharmacokinetics of CB 4332, a Complement Factor I Protein
Alsoud, R. A., Moan, N. L., Holten-Andersen, L., Knudsen, T., Lennernäs, H., & Simonsson, U. S. H. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.06.022 · Cited by 4
A Simple Method for the Prediction of Human Concentration–Time Profiles and Pharmacokinetics of Antibody–Drug Conjugates (ADC) from Rats or Monkeys
Mahmood, I. (2022) · Antibodies · doi:10.3390/antib11020042 · Cited by 4
Predicting Human Bioavailability of Subcutaneously Administered Monoclonal Antibodies Using Non-human Primate Linear Clearance and Antibody Isoelectric Point
Zou, P. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00818-1 · Cited by 4

Authors: Ling, J., Zhou, H., Jiao, Q., & Davis, H. M.
Corresponding author: Ling, Jie
ORCID: Ling, Jie
Zhou, Honghui
Venue: The Journal of Clinical Pharmacology
Publisher: Wiley
Published: 2009-12
Volume: 49
Issue: 12
Pages: 1382-1402
ISSN: 0021-9754 (ISSN-L)
0091-2700
1552-4604
DOI: 10.1177/0091270009337134
OpenAlex: W2011077241
Cited by: 144
References: 68
Citations by year: 2026: 4 · 2025: 4 · 2024: 15 · 2023: 5 · 2022: 7 · 2021: 10 · 2020: 6 · 2019: 8 · 2018: 6 · 2017: 9 · 2016: 10 · 2015: 14 · 2014: 11 · 2013: 11 · 2012: 10
FWCI: 1.15
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 1192 d)
Locations: The Journal of Clinical Pharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords: interspecies scaling, therapeutic monoclonal antibodies, soluble receptor, cell surface receptors, receptor-mediated clearance
MeSH terms: Animals, Antibodies, Monoclonal, Humans, Metabolic Clearance Rate, Species Specificity, Models, Animal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks